Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys -- Data published in the American ...

CMV viremia was detected using PCR analysis during the 12-week prophylaxis period in 2 (11%) of 19 patients in the ganciclovir group and all 23 patients in the deferred-therapy group. [7] However, six ...

A new study found that people with cytomegalovirus (CMV) infection may be more likely to develop systemic lupus erythematosus (SLE), and CMV could influence how the disease starts.

Minnesota's new universal newborn screening program for congenital cytomegalovirus (CMV) identified infants with neurologic abnormalities and those at risk for permanent hearing loss who otherwise ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that, while often latent in the general population, can become reactivated in individuals with compromised immune systems. Inflammatory bowel disease ...

A VIRAL INFECTION THAT IMPACTS UP TO 5% OF BABIES. AND WE’RE GOING TO TALK ABOUT IT. LET’S TALK ABOUT IT WITH DOCTOR KRISTEN MOFFITT, AN INFECTIOUS DISEASE SPECIALIST AT BOSTON CHILDREN’S HOSPITAL.

Cytomegalovirus (CMV) is a ubiquitous member of the Herpesviridae family that can establish latent infections in humans but may reactivate to cause disease in both immunocompromised and, increasingly, ...

Credit: Getty Images. Prevymis is a CMV DNA terminase complex inhibitor. The Food and Drug Administration (FDA) has approved Prevymis ® (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in ...

Please provide your email address to receive an email when new articles are posted on . Letermovir was first approved in 2017 for high-risk stem cell transplant recipients. CMV is relatively common in ...